PubRank

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28203617)

Published in Neurol Neuroimmunol Neuroinflamm on February 03, 2017

Authors

Sibylle C Hodecker1, Jan-Patrick Stellmann1, Sina C Rosenkranz1, Kim Young1, Brigitte Holst1, Manuel A Friese1, Christoph Heesen1

Author Affiliations

1: Institute for Neuroimmunology and Multiple Sclerosis (S.C.H., J.-P.S., S.C.R., K.Y., M.A.F., C.H.), Department of Neurology (S.C.H., J.-P.S., S.C.R., K.Y., C.H.), and Department of Diagnostic and Interventional Neuroradiology (B.H.), University Medical Center Hamburg-Eppendorf, Germany.

Articles cited by this ↗

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol (2014) 1.53

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol (2014) 1.27

CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: A systematic review. Cytokine (2015) 1.11

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol (2015) 1.11